← Back to Search

Other

E-Cigarettes for COPD

Phase 2
Waitlist Available
Led By Diann E Gaalema, PhD
Research Sponsored by University of Vermont
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up intake assessment
Awards & highlights

Study Summary

This trial studies whether vaping or smoking is healthier for people with lung disease.

Who is the study for?
This trial is for English-speaking adults over 40 in the Burlington, VT area who smoke daily and have no plans to quit soon. Participants must have a confirmed pulmonary disease like COPD, chronic bronchitis, emphysema, or asthma-COPD overlap syndrome. Those with recent medical instability or unable to perform home measurements cannot join.Check my eligibility
What is being tested?
The study aims to compare the effects of using e-cigarettes versus continuing regular smoking on lung and heart health in patients with existing lung diseases. It may also explore if financial incentives influence participants' choices regarding these options.See study design
What are the potential side effects?
Potential side effects from e-cigarette use could include throat irritation, coughing, shortness of breath, increased heart rate and blood pressure changes. The exact side effects will be studied as part of this trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~intake assessment
This trial's timeline: 3 weeks for screening, Varies for treatment, and intake assessment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Chronic Obstructive Airway Disease
Baseline FEV1/FVC Ratio
Baseline Fractional Exhaled Nitric Oxide (FeNO)
+20 more
Secondary outcome measures
Baseline Blood Pressure
Baseline Heart Rate
Change From Baseline Heart Rate at 2 weeks
+5 more
Other outcome measures
Baseline Carbon Monoxide (CO)
Nicotine Dependence
Baseline Minnesota Tobacco Withdrawal Scale (MNWS)
+13 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: E-CigaretteExperimental Treatment2 Interventions
Participants in this arm will smoke electronic cigarettes for two weeks. E-cigarettes (either JUUL or Vuse Alto) and pods (JUUL: Virginia tobacco flavor at 3% or 5% nicotine concentration; Vuse Alto: golden tobacco flavor at 1.8%, 2.4%, or 5% nicotine concentration) will be provided.
Group II: Combustible CigaretteActive Control1 Intervention
Participants in this arm will smoke their usual brand of combustible cigarettes for two weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Financial Incentives
2018
Completed Phase 2
~11460

Find a Location

Who is running the clinical trial?

University of VermontLead Sponsor
270 Previous Clinical Trials
3,743,774 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,485 Previous Clinical Trials
2,622,359 Total Patients Enrolled
Diann E Gaalema, PhDPrincipal InvestigatorUniversity of Vermont
~7 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top